Want to see ONCY full AI Analyst Report?
Total Valuation
Oncolytics Biotech has a market cap or net worth of $107.63M. The enterprise value is $110.07.
Market Cap$107.63M
Enterprise Value$110.07
Share Statistics
Oncolytics Biotech has 127,510,506 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding127,510,506
Owned by Insiders1.68%
Owned by Institutions0.94%
Financial Efficiency
Oncolytics Biotech’s return on equity (ROE) is 5.52 and return on invested capital (ROIC) is -1250.57%.
Return on Equity (ROE)5.52
Return on Assets (ROA)-2.76
Return on Invested Capital (ROIC)-1250.57%
Return on Capital Employed (ROCE)-14.14
Revenue Per Employee0.00
Profits Per Employee-991.69K
Employee Count29
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncolytics Biotech is ―. Oncolytics Biotech’s PEG ratio is -0.08.
PE Ratio―
PS Ratio0.00
PB Ratio-22.05
Price to Fair Value-22.05
Price to FCF-5.71
Price to Operating Cash Flow-5.34
PEG Ratio-0.08
Income Statement
In the last 12 months, Oncolytics Biotech had revenue of 0.00 and earned -28.76M in profits. Earnings per share was -0.41.
Revenue0.00
Gross Profit0.00
Operating Income-28.73M
Pretax Income-28.68M
Net Income-28.76M
EBITDA-28.66M
Earnings Per Share (EPS)-0.41
Cash Flow
In the last 12 months, operating cash flow was -26.72M and capital expenditures -11.97K, giving a free cash flow of -26.74M billion.
Operating Cash Flow-26.72M
Free Cash Flow-26.74M
Free Cash Flow per Share-0.21
Dividends & Yields
Oncolytics Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change-16.41%
50-Day Moving Average0.86
200-Day Moving Average0.94
Relative Strength Index (RSI)56.49
Average Volume (3m)1.42M
Important Dates
Oncolytics Biotech upcoming earnings date is Oct 30, 2026, TBA (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateOct 30, 2026
Ex-Dividend Date―
Financial Position
Oncolytics Biotech as a current ratio of 1.12, with Debt / Equity ratio of -7.26%
Current Ratio1.12
Quick Ratio1.12
Debt to Market Cap0.00
Net Debt to EBITDA0.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oncolytics Biotech has paid 79.00K in taxes.
Income Tax79.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Oncolytics Biotech EV to EBITDA ratio is -3.79, with an EV/FCF ratio of -5.40.
EV to Sales0.00
EV to EBITDA-3.79
EV to Free Cash Flow-5.40
EV to Operating Cash Flow-5.40
Balance Sheet
Oncolytics Biotech has $4.12M in cash and marketable securities with $448.00K in debt, giving a net cash position of $3.67M billion.
Cash & Marketable Securities$4.12M
Total Debt$448.00K
Net Cash$3.67M
Net Cash Per Share$0.03
Tangible Book Value Per Share-$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncolytics Biotech is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside517.28% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast2.05%